1339650-77-9

Basic information

• Product Name: 4-chloro-2-mercaptobenzonitrile
• Synonyms: 4-chloro-2-mercaptobenzonitrile
• CAS NO: 1339650-77-9
• Molecular Weight: 169.634
• Mol File: 1339650-77-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 4-chloro-2-mercaptobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-2-mercaptobenzonitrile(1339650-77-9)
• EPA Substance Registry System: 4-chloro-2-mercaptobenzonitrile(1339650-77-9)

Safety Data

• Hazardous Substances Data: 1339650-77-9(Hazardous Substances Data)

Upstream product

• 934180-42-4 2-(benzylthio)-4-chlorobenzamide 
• 131002-01-2 2-bromo-4-chlorobenzamide 
• 57381-49-4 2-bromo-4-chloro-benzonitrile 
• 57381-51-8 4-chloro-2-fluorobenzonitrile 

Downstream Products

• 935433-81-1 2-((2-amino-4-carboxyphenyl)thio)-4-chlorobenzoic acid 

Relevant articles and documents

NOVEL GALACTOSIDE INHIBITOR OF GALECTINS

The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

NOVEL GALACTOSIDE INHIBITOR OF GALECTINS

The present invention relates to a compound of the general formula (I) wherein the pyranose ring is a-D-galactopyranose, R1 is selected from the group consisting of (II) wherein the asterix 1 * indicates the carbon atom of the heteroaromatic ring that is covalently attached to the triazole group of formula (I). The compound of formula (I) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.

HEPATITIS B CORE PROTEIN MODULATORS

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.